Allarity Therapeutics Inc. (ALLR)
NASDAQ (CM) NASDAQ (CM) Primary 
Levi & Korsinsky Announces an Investigation on Behalf of Allarity Therapeutics, Inc. (ALLR) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / July 31, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR Investors Can Join The Allarity Therapeutics Inc Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 31, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Levi & Korsinsky Reminds Shareholders of an Investigation into Allarity Therapeutics, Inc. (ALLR) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
Wolf Haldenstein Adler Freeman & Herz LLP Announces That It Is Investigating Allarity Therapeutics, Inc. for Potential Violations of Federal Securities Laws
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein"), a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in Allarity Therapeutics, Inc. (NASDAQ:ALLR) ("Allarity" or "the Company"). The investigation focuses on whether the Company issued false and/or misleading statements and/or did not disclose information pertinent to investors.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Allarity Therapeutics, Inc. (ALLR) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ:ALLR). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
ALLR ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Allarity Therapeutics, Inc.
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Allarity Therapeutics, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / July 30, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR). Investors who purchased Allarity securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ALLR.
ALLR Investors Can Participate In The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATTENTION ALLR SHAREHOLDERS: Investors who lost money on Allarity Therapeutics, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
ALLR Investors Can Join The Allarity Therapeutics, Inc. Securities Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Allarity Therapeutics, Inc. ("Allarity" or "the Company") (NASDAQ:ALLR) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Investors who lost money on Allarity Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - ALLR
NEW YORK, NY / ACCESSWIRE / July 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Allarity Therapeutics, Inc. ("Allarity") (NASDAQ:ALLR) concerning possible violations of federal securities laws. Allarity disclosed on July 22, 2024, that it received a Wells Notice from the SEC concerning "the Company's disclosures regarding meetings with the United States Food and Drug Administration (the "FDA") regarding the Company's NDA for Dovitinib or Dovitinib-DRP, which was submitted to the FDA in 2021.
